AstraZeneca invests $1.5bn in Singapore facility for next-generation cancer drugs

The manufacturing facility, supported by Singapore's Economic Development Board, is for antibody drug conjugates, and will be designed to be "zero carbon" from its first day of operation in 2029.

Andrew Tjaardstra

May 21, 2024

British-Swedish pharmaceutical giant AstraZeneca has said it plans to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), to help enhance the global supply of its ADC portfolio, according to a May 20 media release.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.